Strs Ohio grew its holdings in Glaukos Co. (NYSE:GKOS) by 900.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,000 shares of the medical instruments supplier’s stock after purchasing an additional 900 shares during the quarter. Strs Ohio’s holdings in Glaukos were worth $49,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. US Bancorp DE boosted its position in Glaukos by 137.9% during the third quarter. US Bancorp DE now owns 590 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 342 shares during the last quarter. Glenmede Trust Co. NA boosted its position in Glaukos by 240.6% during the second quarter. Glenmede Trust Co. NA now owns 831 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 587 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in Glaukos during the first quarter worth approximately $55,000. Canada Pension Plan Investment Board purchased a new position in Glaukos during the second quarter worth approximately $104,000. Finally, PNC Financial Services Group Inc. raised its stake in Glaukos by 99.6% during the second quarter. PNC Financial Services Group Inc. now owns 2,735 shares of the medical instruments supplier’s stock worth $105,000 after purchasing an additional 1,365 shares during the period.
A number of equities analysts have weighed in on GKOS shares. JPMorgan Chase & Co. downgraded shares of Glaukos from a “neutral” rating to an “underweight” rating and set a $50.00 price target on the stock. in a research note on Thursday, October 8th. Oppenheimer started coverage on shares of Glaukos in a research note on Tuesday, December 8th. They set a “market perform” rating and a $73.00 price target on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised shares of Glaukos from a “sell” rating to a “neutral” rating and increased their price target for the stock from $50.00 to $72.00 in a research note on Wednesday, December 16th. BidaskClub downgraded shares of Glaukos from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Piper Sandler raised their target price on shares of Glaukos from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $58.09.
Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.37. The business had revenue of $64.83 million during the quarter, compared to analyst estimates of $53.74 million. Glaukos had a negative net margin of 33.61% and a negative return on equity of 7.99%. The business’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the business earned ($0.10) EPS. On average, analysts forecast that Glaukos Co. will post -1.49 earnings per share for the current fiscal year.
In other Glaukos news, Director William J. Phd Link sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $67.97, for a total transaction of $3,398,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.20% of the stock is currently owned by company insiders.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Recommended Story: The primary rules of Elliott Wave theory
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.